1. Introduction {#sec1}
===============

Colorectal cancer (CRC) is the third most prevalent cancer globally after lung and breast cancer \[[@B1], [@B2]\], and its incidence has increased in recent years along with an increasing number of old people \[[@B3]\]. According to the literature, 45.5% of the incidence and mortality of CRC in China is attributable to unhealthy lifestyles and environmental risk factors including obesity, alcohol consumption, smoking, physical inactivity, and dietary factors \[[@B4]\]. The treatment and prognosis of approximately half of CRC patients with late-stage disease are unsatisfactory owing to resistance to treatment and distant metastasis \[[@B2]\]. Among CRC patients with liver metastases, less than 20% are suitable candidates for surgical intervention \[[@B5]\]. The inhibition of apoptosis in the epithelium of the CRC may contribute to malignancy \[[@B6]\], although the precise molecular mechanisms responsible for metastasis in CRC remain unclear \[[@B7]\]. The identification of novel diagnostic markers and risk factors for CRC is therefore required.

Retinoic acid (RA), a metabolite or analog of vitamin A, is the active form of retinoid with biological functions in processes including cellular proliferation and differentiation, exerted through its receptors, A receptor (RAR) and X receptor (RXR). These receptors each include an *α*, *β*, and *γ* component. Several studies have indicated that RA might be effective in the treatment of malignancies. All-trans RA-based chemotherapy has been used as standard therapy for promyelocytic leukemia, with remission rates of more than 90% \[[@B8], [@B9]\]. Previous researchers have also reported that RAR*β* protein is epigenetically silenced with tumor progression, indicating that RAR*β* might be a tumor-suppressor gene \[[@B10]--[@B12]\].

Some studies have shown that decreased or absent RAR*β* expression correlates with an increase in metastatic processes in various tumor types, including breast cancer and cancers of the digestive tract. However, little has been reported on its role in CRC, particularly its tumor suppressor function \[[@B10]--[@B12]\].

In this study, we evaluated the level of RAR*β* expression in human CRC tissues compared with corresponding tumor-adjacent tissues from the same patients and assessed the relationship between RAR*β* expression and clinical prognosis.

2. Materials and Methods {#sec2}
========================

2.1. Patients and Tissue Microarray Analysis {#sec2.1}
--------------------------------------------

Formalin-fixed and paraffin-embedded tumor samples and corresponding normal adjacent tissues were obtained from CRC patients treated at the Affiliated Hospital of Nantong University between January 2008 and December 2008. The included patients did not receive neoadjuvant radiation, neoadjuvant chemotherapy, or immunotherapy. The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki), and the study protocol was approved by the ethics committee of the *Affiliated Hospital of Nantong University.*

Immunohistochemistry (IHC) with tissue microarrays (TMAs) was used to assess RAR*β* expression in 234 patients with CRC. The average patient age was 60 years, (range: 34--92 years). Clinicopathological parameters including sex, age, tumor stage, tumor diameter, lymph node metastasis, and differentiation were obtained from patient medical records. Overall survival was evaluated from the date of surgical resection until death or the end of the follow-up period. Tumor stage was evaluated according to CRC TNM staging guidelines, version 7 of the World Health Organization classification.

TMAs were constructed as described previously \[[@B13]\]. Following hematoxylin and eosin staining, representative tumor areas were labeled in paraffin blocks. Specimen samples (2 mm in diameter) were prepared and sequentially aligned into fixed paraffin blocks, from which 4 *μ*m optimum sections were prepared \[[@B13]\].

2.2. Immunohistochemical Analysis {#sec2.2}
---------------------------------

We performed IHC on CRC tissues using a primary antibody against RAR*β*. In brief, tissue sections were deparaffinized and antigen retrieval was performed by boiling under high pressure in 0.01 M citrate buffer (pH 7.0) for 5 minutes. Next, sections were incubated with goat serum reagent in phosphate buffered saline (PBS) for 10 minutes to block nonspecific binding. Tissues were then incubated with primary rabbit anti-RAR*β* antibody (1 : 300, ab124701; Abcam, Cambridge, MA, this rabbit monoclonal antibody is against human RAR*β* amino acids 400 to the C-terminus following the instruction of the manufacturer) overnight at 4°C and subsequently incubated with goat anti-rabbit HRP (Dako, Carpinteria, CA) as secondary antibody for 30 minutes, followed by three washes with PBS. Immunostained CRC sections were evaluated by two experienced pathologists under blinded conditions.

2.3. Statistical Methods {#sec2.3}
------------------------

The percentage of RAR*β*-positive cells was scored from 0%--100%. The staining intensity of RAR*β*-positive cells was defined as follows: 0, 1, 2, or 3 for negative, weak, moderate, or strong intensity, respectively. To evaluate statistical significance, an appropriate cut point was established based on RAR*β* expression score and overall survival using the X-tile software program (the Rimm Lab, Yale University, New Haven, CT). The final sum of percentage of RAR*β*-positive cells and intensity score represented the RAR*β* immunostaining score.

A chi-square test was used to compare protein expression of RAR*β* in CRC tissues with corresponding tumor-adjacent tissues and to evaluate the association between RAR*β* protein expression and clinicopathological variables. Kaplan--Meier survival curves and the log-rank test were used to calculate the overall survival rate. The prognostic significance of univariate data models was examined using a multivariate Cox regression analysis. We did univariate analysis using clinical parameters like gender, age, RAR*β* expression, and others, respectively. Then, all clinical parameters that meet *p*value \< 0.05 in univariate analysis were recruited into multivariate analysis. *p*value \< 0.05 was accepted as statistically significant. All analyses were performed using IBM SPSS software version 22 (SPSS Inc., Chicago, IL).

2.4. Validation of RAR*β* Expression in CRC {#sec2.4}
-------------------------------------------

To validate RAR*β* expression and its relationship with clinical parameters in CRC, we explored expression of RAR*β* mRNA in online database Oncomine (<https://www.oncomine.org>). Two CRC datasets were used (Bittner Colon dataset: 373 samples and TCGA dataset: 237 samples).

3. Results {#sec3}
==========

3.1. RAR*β* Protein Expression in CRC Tissues {#sec3.1}
---------------------------------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, RAR*β* expression was primarily observed in the cytoplasm of CRC cells. In CRC samples from 236 patients, RAR*β* expression was detected in 30.8% of samples compared with 58.8% of corresponding peritumoral tissue samples. RAR*β* protein expression was significantly lower in CRC samples compared with adjacent matched tumor tissues (*χ*^2^ = 18.767, *p* \< 0.001) ([Table 1](#tab1){ref-type="table"}).

3.2. Relationship between RAR*β* Expression and Clinicopathological Characteristics of CRC Patients {#sec3.2}
---------------------------------------------------------------------------------------------------

We examined the correlation between clinicopathological parameters and RAR*β* immunoreactivity ([Table 1](#tab1){ref-type="table"}). Our data indicate that RAR*β* immunoreactivity was significantly correlated with gender (*p* = 0.048), tumor differentiation (*p* = 0.014), and tumor TNM stage (*p* = 0.036). However, no association was observed between RAR*β* expression and clinicopathological parameters including age, tumor diameter, lymph node metastasis, and distant metastasis ([Table 1](#tab1){ref-type="table"}).

3.3. Univariate and Multivariate Analysis of Prognostic Factors {#sec3.3}
---------------------------------------------------------------

Univariate Cox regression tests revealed that low RAR*β* protein expression (*p* = 0.001), tumor TNM stage (*p* = 0.002), distant metastasis (*p* = 0.001), and differentiation (*p* = 0.006) were inferior prognostic factors for overall survival ([Table 2](#tab2){ref-type="table"}). A multivariate Cox proportional hazards regression model demonstrated that negative or low RAR*β* expression (*p* = 0.001) and TNM stage (*p* = 0.030) were strong predictors of overall survival ([Table 2](#tab2){ref-type="table"}).

Following surgical resection for CRC, Kaplan--Meier survival curves showed that RAR*β*-positive tumors and early-stage cancer (TNM stage I) were associated with longer overall survival compared with RAR*β*-negative tumors and advanced cancer (TNM stages II--IV) in CRC patients (Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

3.4. Relationship between RAR*β* Protein Expression and Prognosis {#sec3.4}
-----------------------------------------------------------------

To assess the correlation between RAR*β* mRNA expression and its clinical parameters of CRC patients, we analyzed data in the Oncomine database and found that the expression of RAR*β* mRNA correlates negatively with CRC TNM stages (*p* \< 0.05) ([Figure 4](#fig4){ref-type="fig"}). We also analyzed data in the TCGA database and found that low or no RAR*β* expression was shown in CRC tissues compared with high RAR*β* expression in benign noncancerous tissues ([Figure 5](#fig5){ref-type="fig"}). These results analyzed using the Oncomine and TCGA databases (Bittner Colon dataset: 373 samples and TCGA dataset: 237 samples) were consistent with our RAR*β* protein expression data in the previous research, which suggested that high RAR*β* expression was a favorable prognostic factor in CRC.

4. Discussion {#sec4}
=============

As previously reported \[[@B14]\], RAR*β* is the most commonly expressed RAR subtype in CRC. The expression position of RAR*β* is primarily localized in the CRC cellular cytoplasm. RAR*β* has been shown to function as a tumor suppressor, representing an interesting target in cancer research \[[@B10]--[@B12]\]. Indeed, our data suggest that RA-mediated apoptosis in human CRC cells and the significant tumor suppressive effects of RAR*β* may contribute to the chemopreventive actions of retinoid. Recent reports have also indicated that RA, and RAR*β* agonists in particular, inhibits invasion and the migratory potential of breast cancer and endometrial cancer cells \[[@B15]\]. In parallel, the RAR*α*-specific agonist BMS453 significantly reduced the viability of colorectal cells. These results indicate the potential relevance of RAR*β* expression kinetics to the antitumor effect of RAR*β* in CRC. Importantly, the correlation between RAR*β* expression and clinicopathological parameters or prognosis in CRC has been less reported. Given that several studies have shown that marker protein E-cadherin and RAR*β* expression were downregulated in breast cancer samples and that decreased E-cadherin expression is linked to distant metastasis in patients with CRC, we propose that RAR*β* expression may also be relevant in CRC.

An understanding of the multiple prognostic factors impacting survival is critical to the management of cancer after surgical resection \[[@B16], [@B17]\]. In the present study, we investigated the association between RAR*β* cellular expression and clinicopathological parameters in CRC patients utilizing TMA and appropriate statistical analyses, focusing on the level of RAR*β* expression in CRC specimens compared with adjacent tumor specimens. Our data showed that CRC patients expressing low levels of RAR*β* protein were more likely to have a poor prognosis compared with those expressing high levels of RAR*β* protein in tumors. Although RAR*β* also showed weak expression in tumor-adjacent tissues, high RAR*β* protein expression was associated with a higher overall survival rate, indicating that RAR*β* expression might play a critical role in tumorigenesis among CRC patients.

In consideration of these factors, we demonstrated that high RAR*β* expression correlated with increased overall survival of CRC patients. RAR*β* expression was also associated with gender in CRC patients, an observation that has been insufficiently examined in the previous research. This finding may be associated with the physiological features of patients with advanced CRC. The expression among males is gradually decreasing, but it continues to increase among females, with more proportion. Tumor TNM staging has also been shown to be a significant early prognostic factor in CRC in clinical settings ([Table 1](#tab1){ref-type="table"}). Our findings demonstrated that increased RAR*β* expression and early tumor stage are independent prognostic biomarkers in patients with CRC.

Similarly, previous studies reported a significant correlation between RAR*β* expression and esophageal cancer \[[@B18]\], non-small-cell lung cancer \[[@B19], [@B20]\], endometrial cancer, and breast cancer \[[@B21], [@B22]\]. Furthermore, silencing of the RAR*β* gene by promoter hypermethylation is frequently observed in metastatic lung, brain, and bone lesions compared with primary breast cancer \[[@B23]\]. RAR*β* hypermethylation has been found in 92% of endometrial cancers and 75% of endometrial hyperplasias \[[@B24]\]. Previous studies have demonstrated various relationships between clinicopathological parameters and RAR*β* expression in different types of cancer. Taken together, the evidence suggests that RAR*β* expression is reduced in human tumor cells, likely because of the hypermethylation of its promoter \[[@B24], [@B25]\]. RAR*β* appears to be associated with multiple human regulatory pathways, further indicating its critical role in CRC.

RAR*β* comprises three major isoforms, *β*1, *β*2, and *β*4, with different biological functions. RAR-*β*2 is the most abundant and the major RA-inducible isoform, and thus the term RAR*β* in the literature usually refers to the RAR-*β*2 isoform \[[@B26]\]. Collectively, one of the most important functions of retinoids is their antitumor activity, including the inhibition of tumor growth and the promotion of apoptosis, which has led to their function as chemotherapeutic agents \[[@B11], [@B27]\]. Although the therapeutic efficacy of retinoids remains controversial based on previous studies, the future study interestingly raises various hypotheses \[[@B28]\].

In summary, previous studies have shown the potential of RA for the treatment of malignancies, given its biological characteristics. Our findings indicate that RAR*β* protein expression is decreased in CRC compared with normal colorectal tissues and is also decreased in tumor tissues compared with corresponding adjacent tissue, indicating that RAR*β* might have a major role in the suppression of tumor invasion and metastasis. Inactivation of the RAR*β* gene might therefore lead to carcinogenesis. It therefore represents a promising candidate for the development of molecular-targeted therapies to ensure a more favorable prognosis for patients with CRC.

As a result of limitations of the present study size and the restriction of the TMA observational findings, further in vivo and in vitro studies are therefore required to examine the anticancer effect of RAR*β* in CRC tumor biology, including the inhibition of cell proliferation, apoptosis, and migration and the significance of RAR*β* and its crosstalk with other markers to increasing the understanding of RAR*β* mechanisms in CRC.

In conclusion, RAR*β* may be utilized as a prognostic factor in the management of CRC and represents a novel therapeutic target in CRC therapy.
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![Immunohistochemical staining was carried out on paraffin-embedded 4 *μ*m sections, and representative patterns of RAR*β* protein expression in colorectal cancer (a) and peritumoral tissue (b) are shown. In colorectal cancer tissues, no expression was observed (A1 and A2). In adjacent normal colorectal tissues, high RAR*β* expression was observed (B1 and B2). A1 and B1: original magnification ×40 (bar = 500 *μ*m): A2 and B2: ×400 (bar = 50 *μ*m).](DM2019-7138754.001){#fig1}

![Patients with low or no RAR*β* expression (blue line) exhibited significantly poorer survival compared with the high-expression group (green line).](DM2019-7138754.002){#fig2}

![Kaplan--Meier survival curves demonstrate that survival of patients with stage II and stage III--IV CRC tumors is significantly reduced with patients with stage I disease.](DM2019-7138754.003){#fig3}

![The expression of RAR*β* mRNA correlates negatively with the TNM stages (*p* \< 0.05). Among 373 samples of Bittner Colon dataset, we utilized 300 samples of the colon adenocarcinoma which is the most common malignancy of the gastrointestinal tract.](DM2019-7138754.004){#fig4}

![RAR*β* showed higher expression in benign noncancerous tissues compared with colorectal cancer in 237 samples of TCGA dataset.](DM2019-7138754.005){#fig5}

###### 

Correlation of RAR*β* expression with clinicopathological characteristics in patients with colorectal cancer.

  RAR*β*                     *n*    Low or no expression   High expression   Pearson *χ*^2^   *p*
  -------------------------- ------ ---------------------- ----------------- ---------------- ---------------
  Gender                                                                     3.926            **0.048** ^∗^
   Male                      74     56 (75.70)             18 (24.30)                         
   Female                    43     25 (58.10)             18 (41.90)                         
  Age at diagnosis (years)                                                   0.202            0.653
   ≤60                       42     28 (66.70)             14 (33.30)                         
   \>60                      75     53 (70.70)             22 (29.30)                         
  Tumor diameter (cm)                                                        0.396            0.529
   ≤2                        9      7 (77.80)              2 (22.20)                          
   \>2                       105    71 (67.60)             34 (32.40)                         
                             3^a^                                                             
  Differentiation                                                            5.978            **0.014** ^∗^
   Well                      95     61 (64.20)             34 (35.80)                         
   Poor                      22     20 (90.90)             2 (9.10)                           
  Lymph node metastasis                                                      3.772            0.052
   No metastasis             69     43 (62.30)             26 (37.70)                         
   Metastasis                48     38 (79.20)             10 (20.80)                         
  Distant metastasis (M)                                                     0.590            0.442
   No metastasis             111    76 (68.50)             35 (31.50)                         
   Metastasis                6      5 (83.30)              1 (16.70)                          
  Stage grouping with TNM                                                    6.642            **0.036** ^∗^
   Stage I                   29     15                     14                                 
   Stage II                  39     27                     12                                 
   Stage III-IV              49     39                     10                                 

^a^Immeasurable tumor diameter, 3 cases; ^∗^*p* \< 0.05.

###### 

Univariate and multivariate analysis of prognostic factors for overall survival in CRC patients.

  --------------------------------------------------------------------------------------------------------------------------------
  Characteristic                Univariate analysis   Multivariate analysis                                          
  ----------------------------- --------------------- ----------------------- -------------- ------- --------------- -------------
  RAR*β* expression             0.032                 **0.001** ^∗^           0.004 0.232    0.038   **0.001** ^∗^   0.005 0.278

  Tumor diameter (cm)\          4.596                 0.132                                                          
  ≤2 vs \>2                                                                                                          

  Lymph node metastasis\        1.379                 0.268                   0.781 2.434                            
  No metastasis vs metastasis                                                                                        

  Distant metastasis (M)\       5.189                 **0.001** ^∗^           2.028 13.272                           
  No metastasis vs metastasis                                                                                        

  Stage grouping with TNM\      1.758                 **0.002** ^∗^           1.235 2.503    1.523   **0.030** ^∗^   1.043 2.225
  Stage I vs II vs III-IV                                                                                            

  Gender\                       1.584                 0.148                   0.849 2.953                            
  Male vs female                                                                                                     

  Age at diagnosis (years)\     1.121                 0.708                   0.615 2.044                            
  ≤60 vs \>60                                                                                                        

  Differentiation\              0.418                 **0.006** ^∗^           0.224 0.780    0.687   0.243           0.366 1.289
  Well vs moderate vs poorly                                                                                         
  --------------------------------------------------------------------------------------------------------------------------------

^∗^ *p* \< 0.05.
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